Advances in pancreatic neuroendocrine tumor treatment: [3]

New England Journal of Medicine

Volumn 364, Issue 19, 2011, Pages 1872-1873

  Castellano, Daniel ^a   Grande, Enrique ^b   Barriuso, Jorge ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOSTATIN DERIVATIVE; SUNITINIB;

DRUG EFFICACY; DRUG RESPONSE; HUMAN; LETTER; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRROLES;

EID: 79955907840     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Barriuso J, Grande E, Quindós Varela M, et al. Sunitinib efficacy and tolerability in patients with neuroendocrine tumors out of a trial: a Spanish multicenter cohort. In: Program and abstracts of the 35th European Society for Medical Oncology Congress, Milan, October 8-12, 2010. abstract.
2. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-10.